December 1, 2022

Volume XII, Number 335

Advertisement

December 01, 2022

Subscribe to Latest Legal News and Analysis

November 30, 2022

Subscribe to Latest Legal News and Analysis

November 29, 2022

Subscribe to Latest Legal News and Analysis
Advertisement

Developers Take Note: FDA Issues Clinical Decision Support Software Final Guidance

On September 27, 2022, the Food and Drug Administration (FDA) issued its much anticipated final guidance for industry and FDA Staff, Clinical Decision Support Software. This guidance follows the draft Clinical Decision Support Software guidance issued on September 27, 2019. The final guidance is particularly important as developers seek clarity regarding the regulatory status of software functions that utilize algorithms to either support or provide clinical decisions for use by health care providers (HCPs). While the draft guidance opined upon clinical decision support software (CDS) intended for use by patients are caregivers, the final guidance noted that FDA’s existing digital health policies continue to apply to such software functions such that software functions that support or provide recommendations to patients or caregivers – not HCPs – meet the definition of a device.

FDA regulates software that meets the definition of a device in section 201(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which includes software intended to support HCP decision-making regarding the diagnosis, treatment, prevention, cure, or mitigation of diseases or other conditions, otherwise known as CDA. In its guidance, FDA clarifies types of CDS software functions that are excluded from the definition of a medical device by meeting all four of the criteria articulated in section 520(o)(1)(E) of the FD&C Act, which requires that the device is:

(1) not intended to acquire, process, or analyze a medical image or a signal from an in vitro diagnostic device or a pattern or signal from a signal acquisition system (Criterion 1);

(2) intended for the purpose of displaying, analyzing, or printing medical information about a patient or other medical information (e.g., peer-reviewed clinical studies and clinical practice guidelines) (Criterion 2);

(3) intended for the purpose of supporting or providing recommendations to an HPC about prevention, diagnosis, or treatment of a disease or condition (Criterion 3); and

(4) intended for the purpose of enabling such HCPs to independently review the basis for such recommendations that such software presents so that it is not the intent that such HCPs rely primarily on any of such recommendations to make a clinical diagnosis or treatment decision regarding an individual patient (Criterion 4).

Criterion 1

FDA considers software functions that assess or interpret the clinical implications or clinical relevance of a signal, pattern, or medical image to be software functions that do not meet Criterion 1 because they acquire, process, or analyze. Such devices are subject to FDA regulation and oversight. Note, however, that activity monitors or other signal acquisition systems that measure physiological parameters that are not specifically intended or marketed for a purpose identified in the device definition are not medical devices.

Criterion 2

Software functions intended to display, analyze, or print7medical information about a patient or other medical information (e.g., peer-reviewed clinical studies or clinical practice guidelines) meet Criterion 2 and are not medical devices subject to FDA regulation and oversight.

FDA explains that Criterion 1 and Criterion 2 describe the types of data inputs used in devices (Criterion 1) and the types of data inputs used in Non-Device CDS (Criterion 2). 

Criterion 3

FDA interprets Criterion 3 to refer to software that provides condition-, disease-, and/or patient-specific recommendations to an HCP to enhance, inform and/or influence a health care decision (e.g., drug-drug interaction and drug-allergy contraindication notifications to avert adverse drug events) but is not intended to replace or direct an HCP’s judgment and does not include in time-critical decision-making or a specific preventive, diagnostic or treatment output or directive. Criterion 3 software functions present recommendations based on an analysis of patient-specific information to an HCP, who may then incorporate this information into their decision-making about the care of a patient, along with other information and factors of which the HCP is aware. In contrast, software that provides a specific preventive, diagnostic, or treatment output or directive or that addresses a time-critical decision would be a medical device regulated by FDA and subject to FDA oversight.

FDA notes that two aspects of software functionality may affect whether a software function is being used to support or provide recommendations to an HCP: (1) the level of software automation, and (2) the time-critical nature of the HCP’s decision making. Automation bias may occur if software provides an HCP with a single, specific, selected output or solution as opposed to a list of options or complete information for the HCP’s consideration.

Criterion 4

Under criterion 4, the software function must be intended to enable HCPs to independently review the basis for the recommendations presented by the software so that they do not rely primarily on such recommendations, but rather on their own judgment, to make clinical decisions for individual patients. FDA explains that regardless of the complexity of the software and whether or not it is proprietary, the software output or labeling should provide adequate background information in plain language on the input(s), algorithm logic or methods, datasets, and validation. Additionally, relevant sources should be identified and available to and understandable by the HCP user. 

The final guidance released by FDA includes several examples of device and non-device CDS, which should be carefully reviewed by developers when inking an FDA regulatory strategy.

© 2022 Foley & Lardner LLPNational Law Review, Volume XII, Number 271
Advertisement
Advertisement
Advertisement

About this Author

Kyle Faget, Foley Lardner, Government policy lawyer
Partner

Kyle Faget is a Partner and business lawyer with Foley & Lardner LLP. She is a member of the firm’s Government & Public Policy Practice and the Health Care and Life Sciences Industry Teams. Her practice focuses on advising clients on regulatory and compliance matters involving the Food, Drug & Cosmetic Act, the False Claims Act, the Anti-Kickback Statute, the AdvaMed Code, and the PhRMA Code. She also regularly drafts and negotiates agreements required for the development and commercialization of pharmaceutical and medical device products. Prior to joining...

617.502.3292
Advertisement
Advertisement
Advertisement